Literature DB >> 35294766

Use In Silico and In Vitro Methods to Screen Hepatotoxic Chemicals and CYP450 Enzyme Inhibitors.

Yitong Liu1.   

Abstract

In silico and in vitro methods have emerged as valuable tools to rapidly screen and prioritize large numbers of chemicals including new drug entities, food ingredients, and environmental compounds for further in vivo analysis. These methods have been frequently used to conduct screening for a wide range of endpoints including physicochemical properties (e.g., logD), human biokinetic parameters (e.g., metabolism), and human organ toxicities (e.g., hepatotoxicity). This chapter describes a tiered approach of incorporating multiple in silico (quantitative structure-activity relationship, QSAR) and in vitro (e.g., human liver cell models, human liver microsomes) methods into the screening of hepatotoxic chemicals and cytochromes P450 enzyme (CYP) inhibitors. Chemicals are prioritized for further studies (e.g., in vivo animal study) based on the in silico and in vitro results, as well as a literature search for their in vivo exposures (e.g., plasma concentration).
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  CYP enzymes; Hepatotoxicity; Human liver cell models; In silico; In vitro; Inhibitor; QSAR

Mesh:

Substances:

Year:  2022        PMID: 35294766     DOI: 10.1007/978-1-0716-2213-1_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  Biokinetic modeling and in vitro-in vivo extrapolations.

Authors:  Bas J Blaauboer
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2010-02       Impact factor: 6.393

2.  Best of both worlds: combining pharma data and state of the art modeling technology to improve in Silico pKa prediction.

Authors:  Robert Fraczkiewicz; Mario Lobell; Andreas H Göller; Ursula Krenz; Rolf Schoenneis; Robert D Clark; Alexander Hillisch
Journal:  J Chem Inf Model       Date:  2014-12-16       Impact factor: 4.956

Review 3.  Cytochrome P450 Structure, Function and Clinical Significance: A Review.

Authors:  Palrasu Manikandan; Siddavaram Nagini
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

Review 4.  Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment.

Authors:  Barbara A Wetmore
Journal:  Toxicology       Date:  2014-06-05       Impact factor: 4.221

Review 5.  Drug-Induced Liver Injury.

Authors:  Kurt Fisher; Raj Vuppalanchi; Romil Saxena
Journal:  Arch Pathol Lab Med       Date:  2015-07       Impact factor: 5.534

6.  Incorporation of absorption and metabolism into liver toxicity prediction for phytochemicals: A tiered in silico QSAR approach.

Authors:  Yitong Liu
Journal:  Food Chem Toxicol       Date:  2018-05-18       Impact factor: 6.023

7.  Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.

Authors:  Teerachat Saeheng; Kesara Na-Bangchang; Juntra Karbwang
Journal:  Eur J Clin Pharmacol       Date:  2018-07-05       Impact factor: 2.953

8.  Liver toxicity of anthraquinones: A combined in vitro cytotoxicity and in silico reverse dosimetry evaluation.

Authors:  Yitong Liu; Mapa S T Mapa; Robert L Sprando
Journal:  Food Chem Toxicol       Date:  2020-03-30       Impact factor: 6.023

9.  Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitro.

Authors:  Yitong Liu; Mapa S T Mapa; Robert L Sprando
Journal:  J Appl Toxicol       Date:  2021-01-12       Impact factor: 3.446

Review 10.  CYP polymorphisms and pathological conditions related to chronic exposure to organochlorine pesticides.

Authors:  Anca Oana Docea; Loukia Vassilopoulou; Domniki Fragou; Andreea Letitia Arsene; Concettina Fenga; Leda Kovatsi; Dimitrios Petrakis; Valerii N Rakitskii; Alexander E Nosyrev; Boris N Izotov; Kirill S Golokhvast; Alexander M Zakharenko; Antonis Vakis; Christina Tsitsimpikou; Nikolaos Drakoulis
Journal:  Toxicol Rep       Date:  2017-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.